These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26578231)

  • 21. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A follow-up study on men tested for BRCA1/BRCA2 mutations: impacts and coping processes.
    Shiloh S; Dagan E; Friedman I; Blank N; Friedman E
    Psychooncology; 2013 Feb; 22(2):417-25. PubMed ID: 22135240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Factors for Distress After Genetic Testing for Hereditary Cancer.
    Voorwinden JS; Jaspers JP
    J Genet Couns; 2016 Jun; 25(3):495-503. PubMed ID: 26475052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hereditary melanoma and predictive genetic testing: why not?
    Riedijk SR; de Snoo FA; van Dijk S; Bergman W; van Haeringen A; Silberg S; van Elderen TM; Tibben A
    Psychooncology; 2005 Sep; 14(9):738-45. PubMed ID: 15744786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling.
    Godard B; Pratte A; Dumont M; Simard-Lebrun A; Simard J
    Genet Test; 2007; 11(1):45-54. PubMed ID: 17394392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment.
    Vos J; Menko FH; Oosterwijk JC; van Asperen CJ; Stiggelbout AM; Tibben A
    Psychooncology; 2013 May; 22(5):1167-76. PubMed ID: 22777929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicians' attitudes toward general screening of the Ashkenazi-Jewish population for prevalent founder BRCA1/2 and LRRK2 mutations.
    Shkedi-Rafid S; Ofer-Bialer G; Meiner V; Calderon-Margalit R
    Public Health Genomics; 2013; 16(4):174-83. PubMed ID: 23816973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early adoption of BRCA1/2 testing: who and why.
    Armstrong K; Weiner J; Weber B; Asch DA
    Genet Med; 2003; 5(2):92-8. PubMed ID: 12644778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parenting through genetic uncertainty: themes in the disclosure of breast cancer risk information to children.
    Sharff ME; DeMarco TA; Mays D; Peshkin BN; Valdimarsdottir HB; Garber JE; Schneider KA; Patenaude AF; Tercyak KP
    Genet Test Mol Biomarkers; 2012 May; 16(5):376-82. PubMed ID: 22085394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of participation in psychosocial telephone counseling following genetic testing for BRCA1 and BRCA2 mutations.
    Halbert CH; Wenzel L; Lerman C; Peshkin BN; Narod S; Marcus A; Corio C; Demarco T; Bellamy S
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):875-81. PubMed ID: 15159322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
    Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
    Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
    Nippert I; Schlegelberger B;
    Community Genet; 2003; 6(4):249-58. PubMed ID: 15331871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.
    J Clin Oncol; 1996 May; 14(5):1730-6; discussion 1737-40. PubMed ID: 8622094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.
    Lheureux S; Karakasis K; Harter P; Scott C; Bacon M; Bryce J; Le Fur N; Pujade-Lauraine E; Oza AM
    Gynecol Oncol; 2016 Jan; 140(1):90-4. PubMed ID: 26475959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.
    van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A
    Patient Educ Couns; 2007 Jan; 65(1):58-68. PubMed ID: 16872788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort.
    Foster C; Evans DG; Eeles R; Eccles D; Ashley S; Brooks L; Cole T; Cook J; Davidson R; Gregory H; Mackay J; Morrison PJ; Watson M
    Genet Test; 2004; 8(1):23-9. PubMed ID: 15140371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.